Deals19 Jan 2024, 03:13 pm
Glenmark Life Sciences Signs Master Supply Agreement with Leading Japanese Innovator Pharmaceutical Company
AI Summary
Glenmark Life Sciences Limited (GLS) has signed a Master Supply Agreement with a leading Japanese innovator pharmaceutical company to manufacture and supply API in the therapeutic area of urinary anti-spasmodic. The estimated commercial value of this project is expected to be around $5 million. This collaboration is part of GLS's continued efforts in the CDMO space and demonstrates its commitment to fostering strategic alliances that drive innovation.,
Key Highlights
- Glenmark Life Sciences signs Master Supply Agreement with leading Japanese innovator pharmaceutical company
- Estimated commercial value of the project is around $5 million
- Collaboration is part of GLS's continued efforts in the CDMO space
- Demonstrates GLS's commitment to fostering strategic alliances that drive innovation